Back to Stocks

IMA

ImageneBio, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

ImageneBio has successfully transitioned into a streamlined, pure-play immunology company, centering its entire operational focus on the lead asset IMG-007.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative, ImageneBio faces significant financial and operational headwinds. The company's quarterly cash burn increased by over 100% year-over-year, reaching $14.8 million in the first quarter of 2026.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every IMA filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a classic biotech trade-off: a high-conviction clinical asset backed by a recently replenished treasury, balanced against significant structural risks. The successful pivot to a pure-play model and the securing of $30 million in new capital provide the necessary breathing room for the IMG-007 program to advance. However, the acceleration of operating expenses and the admission of material weaknesses in financial controls suggest an organization still struggling with the transition to a public company framework. Ultimately, the investment thesis hinges on the clinical success of IMG-007 and the company's ability to navigate a volatile geopolitical environment affecting its Chinese manufacturing. While the balance sheet is currently sufficient, the long gap until the 2027 data readout creates a window of vulnerability where further dilution or supply chain disruptions could jeopardize the company's path to valuation re-rating.

Selected Quarter

Core Takeaway

ImageneBio has successfully pivoted to a single-asset immunology company with a reinforced balance sheet, but it must now prove it can manage its burn and supply chain through 2027.

Investor Lens

The trade-off is between the high-reward potential of a unique anti-OX40 mAb and the high-risk profile of a cash-burning clinical stage company with internal control issues.

Watch Next

Topline data from the Phase 2b atopic dermatitis study expected in Q4 2027.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.13Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Raised $30 million through a private placement of pre-funded warrants in April 2026.

capital raise
70%
bearishMay 7

Operating expenses increased to $12.1 million as the company scales clinical trials and public company overhead.

margin compression
60%
bearishMay 7

Disclosure of material weakness in internal controls over financial reporting.

regulatory action
50%
bullishMay 7

Raised $30 million through a private placement of pre-funded warrants in April 2026.

capital raise
70%
bearishMay 7

Operating expenses increased to $12.1 million as the company scales clinical trials and public company overhead.

margin compression
60%
bearishMay 7

Disclosure of material weakness in internal controls over financial reporting.

regulatory action
50%
bullishMay 7

Raised $30 million through a private placement of pre-funded warrants in April 2026.

capital raise
70%
bearishMay 7

Operating expenses increased to $12.1 million as the company scales clinical trials and public company overhead.

margin compression
60%
bearishMay 7

Disclosure of material weakness in internal controls over financial reporting.

regulatory action
50%
bullishMay 7

Raised $30 million through a private placement of pre-funded warrants in April 2026.

capital raise
70%
bearishMay 7

Operating expenses increased to $12.1 million as the company scales clinical trials and public company overhead.

margin compression
60%
bearishMay 7

Disclosure of material weakness in internal controls over financial reporting.

regulatory action
50%
bullishMay 7

Raised $30 million through a private placement of pre-funded warrants in April 2026.

capital raise
70%
bearishMay 7

Operating expenses increased to $12.1 million as the company scales clinical trials and public company overhead.

margin compression
60%
bearishMay 7

Disclosure of material weakness in internal controls over financial reporting.

regulatory action
50%
bullishMay 7

Raised $30 million through a private placement of pre-funded warrants in April 2026.

capital raise
70%
bearishMay 7

Operating expenses increased to $12.1 million as the company scales clinical trials and public company overhead.

margin compression
60%
bearishMay 7

Disclosure of material weakness in internal controls over financial reporting.

regulatory action
50%
bullishMay 7

Raised $30 million through a private placement of pre-funded warrants in April 2026.

capital raise
70%
bearishMay 7

Operating expenses increased to $12.1 million as the company scales clinical trials and public company overhead.

margin compression
60%
bearishMay 7

Disclosure of material weakness in internal controls over financial reporting.

regulatory action
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a classic biotech trade-off: a high-conviction clinical asset backed by a recently replenished treasury, balanced against significant structural risks. The successful pivot to a pure-play model and the securing of $30 million in new capital provide the necessary breathing room for the IMG-007 program to advance. However, the acceleration of operating expenses and the admission of material weaknesses in financial controls suggest an organization still struggling with the transition to a public company framework. Ultimately, the investment thesis hinges on the clinical success of IMG-007 and the company's ability to navigate a volatile geopolitical environment affecting its Chinese manufacturing. While the balance sheet is currently sufficient, the long gap until the 2027 data readout creates a window of vulnerability where further dilution or supply chain disruptions could jeopardize the company's path to valuation re-rating.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.